Evaluation of a beef-based chewable formulation of pyrantel pamoate against induced and natural infections of hookworms and ascarids in dogs.
Pyrantel pamoate, formulated in a beef-based chewable tablet, was evaluated for efficacy in dogs against induced and natural infections of Toxocara canis, Toxascaris leonina, Ancylostoma caninum and Uncinaria stenocephala. Dose titration trials were conducted in Canada, the UK and Germany in dogs treated with pyrantel (as pamoate salt) at 0, 2.5, 5 or 10 mg kg-1 body weight. These studies showed that a dose rate of 2.5 mg kg-1, the efficacy of pyrantel against adult T. canis, T. leonina, U. stenocephala and A. caninum was 76.1, 85.6, 100 and 87.9%, respectively. Efficacy at 5 mg kg-1 against the same parasites was 94.2, 92.0, 93.5 and 93.8%, respectively, and at 10 mg kg-1 efficacy was 91.2, 97.6, 98.7 and 91.3%, respectively. No adverse effects due to treatment were seen in any of these trials.
Clark
J N
JN
Merck, Sharp and Dohme Research Laboratories, Rahway, NJ 07065-0900.
Daurio
C P
CP
Barth
D W
DW
Batty
A F
AF
D000284:Administration, Oral; D000724:Ancylostomiasis / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy / Q000662:veterinary*; D009349:Nematode Infections / Q000188:drug therapy / Q000662:veterinary*; D011716:Pyrantel Pamoate / Q000008:administration & dosage / Q000627:therapeutic use*; D014120:Toxocariasis / Q000188:drug therapy / Q000662:veterinary
D011716:Pyrantel Pamoate